Paul’s Slides for George --to put in IMAGING CORE for

ADRC EAB meeting

Summary

We developed 4 major new methods to track brain change, e.g. Alzheimer’s disease or MCI

progression

Can now map disease spreading in the living brain (cortical thickness video maps,

fluid maps of brain change - TBM)

Feasible to map subtle brain changes (~0.5% volume loss) in an individual over 2-4 weeks

Now testing in large trials to distinguish drug effects (galantamine, lithium, antipsychotics)

Cortical Thickness Mapping (used in ~30 papers)- see Thompson et al., 2004 (for an overview)

Example: AIDS Dementia Complex (Thompson et al., Proc. Nat. Acad. Sci., 2005)

Also began to correlate cortical thickness on MRwith FDG-PET in healthy controls and AD (Thompson/Huang/Small)

Who did we train to use our tools?

• Univ. of Pittsburgh ADC (PI: Oscar Lopez) began to use our HP/CTX methods and have submitted ~10 papers on MCI and AD (N=381), HIV-associated dementia (N=53), and semantic dementia. One was in PNAS this month (Thompson et al., 2005)

• Liana Apostolova MD, ADRC, Asst. Prof. (journal papers submitted on cortical thinning in MCI, relation to apathy, hippocampal atrophy in MCI, several in preparation)

• Giovanni Frisoni, Rome, Italy -- submitted several papers using our hippocampal/cortex mapping methods

• Mony de Leon, NYU (learning surface-based PET analysis)• Addition of large longitudinal datasets (G. Bartzokis), presenilin subjects (J.

Ringman), ADNI (M. Weiner/C. Jack - analysis of 200 prep phase scans is now submitted to NeuroImage; not ADRC but further validated methods)

• Began PET-MRI work correlating MRI thickness with FDG-PET in G. Small’s ApoE genotyped normals (N=30 approx., to date; also FDDNP, MPPF; N=6-10; data will be submitted to HBM, Dec 05)

Large-scale automated 3D ventricular mapping in elderly controls, MCI, AD

(N=381; Thompson/UCLA/U. Pittsburgh)

How Can We Best Track Neurodegenerative BrainChange in an Individual?

Thompson et al., Nature 404:190-193 (2000).

Case Study: Mapping Atrophy in a Semantic Dementia PatientThompson/Glaxo study

Changes Internal to the Basal Gangliain a Semantic Dementia Patient (Case Study)

Automated Mappingof

Trajectory of WM Atrophy over time

in a Patient with progressive posterior cortical atrophy and Broca’s area atrophy

(Case Study; P. Thompson et al./U. Queensland/Glaxo)

Promising Biomarker for Trials

Summary

New methods to track brain change, e.g. Alzheimer’s disease progression

Can now map disease spreading in the living

brain (cortical thickness video maps, fluid maps of brain change)

Now testing in large trials to distinguish drug effects (galantamine, lithium, antipsychotics)

Feasible to map subtle brain changes (~0.5% volume loss) in an individual over 2-4 weeks